Sebastian Gensior

The psychedelics industry entered August 2025 with approximately $1.2 billion in combined cash reserves across six major public companies, yet quarterly burn rates exceeding $150 million threaten the sector's viability within 24 months. Following the FDA's rejection of MDMA-assisted therapy in August 2024, which triggered

The great wheel of computing infrastructure turns full circle: from centralized mainframes to distributed systems to cloud centralization and now back to intelligent decentralization. When a16z Abandons Its Own Cloud Gospel In the era of foundation models, multimodal AI, LLMs, and ever-larger datasets, access to raw compute is still one

Biopharma dealmaking slows amid regulatory storm The week of August 18-23, 2025 marked an unusually subdued period for biopharma transactions, with only 14 deals announced compared to typical weekly averages exceeding 25-30 transactions. The total disclosed deal value reached approximately $5.5 billion, though most arrangements featured milestone-heavy structures reflecting

The pharmaceutical industry's adoption of Palantir Technologies reveals a fundamental tension in enterprise software architecture that goes beyond simple market positioning. At its core, this is a story about whether a platform designed for counterterrorism and battlefield intelligence can meaningfully transform drug discovery and clinical trials, or whether

ARCH Venture Partners has raised over $3 billion for its thirteenth fund, cementing its position as one of biotech's most influential venture capital firms. The Chicago-based firm, which originated from a University of Chicago technology transfer initiative in 1986, has evolved into an investment powerhouse managing approximately $12

The recent closure of AlpInvest's $1 billion collateralized fund obligation marks a potential inflection point for biotech financing. This complex financial structure, dormant since the 2008 financial crisis, could unlock trillions in insurance capital for an industry perpetually hungry for funding. But as private equity rushes into pharmaceutical

Where natural selection meets unnatural hotel ballroom lighting In the grand ecosystem of biotechnology conferences, where PowerPoint presentations battle for attention spans and coffee quality determines afternoon session attendance, choosing the right events has become as complex as selecting lead compounds for clinical development. The modern biotech executive faces a

EU AI Act: Pharmaceutical AI Compliance Framework EU AI Act Classification High-Risk AI Systems Pharmaceutical AI Applications Documentation Requirements Risk Assessment Protocols Human Oversight Mandates Infrastructure Implications On-Premises Advantages Cloud Compliance Challenges Legend: Regulatory Framework Compliance Requirements Preferred Solution Standard Process Source: EU AI Act (2024), EMA AI Guidance (2024)

Private equity firms deployed $5.42 billion into biotech and pharmaceutical royalty transactions through 2025, marking a 7% increase from the previous year despite broader market turbulence. The acquisition of HealthCare Royalty Partners by KKR in July 2025, adding $3 billion in assets under management to the private equity giant&

Pharma & biotech deals heat up with $5B+ in transactions The week of August 11-15, 2025 witnessed a striking bifurcation in pharmaceutical and biotech dealmaking: while venture capital remained frozen in an unprecedented funding drought, strategic partnerships and public markets surged with over $5 billion in total transaction value. Major